Aclarion, Inc.
ACON · XNASCIK 1635077fmd_044NY8T8YSJZMW9K6CS191TR7HServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Gross profit | (0) | (0) | (0) | (0) | 0 |
| Research and development | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 2 | 4 | 4 | 5 | 6 |
| Total operating expenses | 3 | 6 | 5 | 5 | 7 |
| Operating income | (3) | (6) | (5) | (6) | (7) |
| Interest expense | 0 | 2 | 0 | 0 | – |
| Other non-operating income (expense) | (2) | (2) | (0) | (1) | (0) |
| Income before taxes | – | (7) | (5) | (7) | (7) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (7) | (5) | (7) | (7) |
| Net income | (5) | (7) | (5) | (7) | (7) |
| Net income to common shareholders | (6) | (7) | (5) | (7) | (7) |